A SNAP-SHOT OF FIRST-LINE ART TREATMENT FAILURE CASES FROM MPUMALANGA PROVINCE ON THE DECENTRALISED PHARMACOVIGILANCE PROGRAMME DATABASE
The increase in ART use comes with the inevitable increase in cases of ART treatment failure, especially that patients are living longer on ART. The main objective of this short study was to conduct an interim review of the Pharmacovigilance database at the National Pharmacovigilance Centre of South Africa in order to profile cases of treatment failure with first-line antiretroviral therapy among HIV-infected patients in Mpumalanga Province. From 2851 ADR reports, 853 were reported for male patients, 1699 females and 299 had no gender reported. A total of 271 patients were diagnosed with treatment failure. 170 of these were female, 78 male and for 23 of the reports, gender was unreported. The mean age of the patients who were reported to have treatment failure was 36 years. The highest number of treatment failure was reported from the age group 31 - 40 years with the majority being females. A strong correlation was observed between female sex and treatment failure. The South African National Pharmacovigilance Centre decentralized Pharmacovigilance database is a useful tool that can be used to consistently monitor and document ART treatment failures.
2. Fairall LR, Bachmann MO, Louwagie GM, van Vuuren C, Chikobvu P, Steyn D, et al. Effectiveness of antiretroviral treatment in a South African program: a cohort study. Archives of Internal Medicine. 2008; 168(1):86-93.
3. Silveira M P, DraschlerMde L, Leite J. C, Pinheiro C A, da Silveira V L. Predictors of undetectable plasma viral load in HIV-positive adults receiving antiretroviral therapy in Southern Brazil. Brazilian Journal of Infectious Disease.2002; 6(4): 164-71.
4. Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-Limited Settings. WHO; 2006.
5. Conradie F, Wilson D, Basson A, et al. The 2012 southern African ARV drug resistance test in guidelines. S. Afr. J. HIV Med. 2012;13:162-167.
6. Rawizz. 17th CROI. Abstract 111;2010.
7. Harries AD, Zachariah R, Van Oosterhout JJ, Reid SD, Hosseinipour MC, Arendt V, et al. The Lancet Infectious Diseases. 2010; 10(1): 60 – 5. (doi:10.1016/S1473-3099(09)70321-4).
8. Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, Larouzé B, Verdon R. Clin Infect Dis.2004; 1;38(9):1311-6.
9. Mpumalanga Provincial Department of Health Report 2012 to 2013. [Internet]. 2013[cited 2014 Sep 02]. Available from:
10. National Antenatal Sentinel HIV and Syphillis Prevalence Survey in South Africa. South Africa: National Department of Health; 2011.
11. Dheda M, Distefano K, Sunduzwayo K, Williams F, Kambafwile H. Journal of AIDS and HIV Research. 2013; 5(9): 370-9. DOI: 10.5897/JAHR2013.0262.
12. Dheda M. Journal of AIDS and HIV Research. 2013; 5(9):357-65. DOI: 10.5897/JAHR2013.02 57.
13. StataCorp. Stata Statistical Software. 12 ed. TX: College Station; StataCorp LP; 2011.
14. Gollogly L. Editorial: Ethical approval for operational research. Bulletin of the World Health Organization; 2006: 84(10).
15. PEPFAR Mpumalanga Fact sheet 2014. [Internet]. 2014[cited 2014 Sep 04]. Available from: http://photos.state.gov/libraries/southafrica/917455/nevhulaudzirk/MP%20Fact%20Sheet_Jan2014.pdf.
16. South African National Aids Council. South Africa: The 2013 Global AIDS Response Progress Report, Pretoria, South Africa; 2013.
17. Statistics South Africa Statistical Release P0302. Mid-year population estimates 2014 [Internet]. 2014[cited 2014 Sep 03]. Available from: http://beta2.statssa.gov.za/publications/P0302/P03022014.pdf.
18. Woldemedhin B, Wabe NT. N Am J Med Sci. 2012; 4(1): 19–23. doi:10.4103/1947-2714.92 898.
19. Prosperi MCF, Fabbiani M, Fanti I, Zaccarelli M, Colafigli M, Mondi A, et al. BMC Infectious Diseases. 2012; 12:296.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM